Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a	Reasons for NA
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		**n/a**	No antibody was used

Cell materials	Yes (indicate where provided:	n/a	
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		**n/a**	No cell line was used
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		**n/a**	No primary culture was used

Experimental animals	Yes (indicate where provided:	n/a	
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		✓	No experimental animal was used
Animal observed in or captured from the field: Provide species, sex and age where possible		✓	No experimental animal was used
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		✓	No experimental animal was used

Plants and microbes	Yes (indicate where provided:	n/a	
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		**n/a**	No plant was used
Microbes: provide species and strain, unique accession number if available, and source		**n/a**	No microbe was used

Human research participants	Yes (indicate where provided:	n/a	
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Materials, Paragraph 3 (Page 5, Line 42-43)		
Provide statement confirming informed consent obtained from study participants.	Materials, Paragraph 3 (Page 5, Line 40-41)		
Report on age and sex for all study participants.	Result, Paragraph 1 (Page 7, Line 73-74)		

Design

Study protocol	Yes (indicate where provided:	n/a	Reason for NA
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		n/a	Not a clinical trial.

Laboratory protocol	Yes (indicate where provided:	n/a	
Provide DOI or other citation details if detailed step-by-step protocols are available.		n/a	No lab experiment was done

Experimental study design (statistics details)	Yes (indicate where provided:	n/a	
State whether and how the following have been done**, or** if they were not carried out.			
Sample size determination	Not carried out		
Randomisation		n/a	observation study
Blinding		n/a	observation study
Inclusion/exclusion criteria	Materials, Paragraph 1 (Page 5, Line 27-30)		

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a	
State number of times the experiment was replicated in laboratory		n/a	No lab experiment was done
Define whether data describe technical or biological replicates		n/a	No lab experiment was done

Ethics	Yes (indicate where provided:	n/a	
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Materials, Paragraph 3 (Page 5, Line 42-43)		
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a	No experimental animal was used
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Materials, Paragraph 3 (Page 5, Line 40-41)		

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a	
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a	No dual use research

Analysis

Attrition	Yes (indicate where provided:	n/a	Reasons for NA
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	No sample is excluded.		

Statistics	Yes (indicate where provided:	n/a	
Describe statistical tests used and justify choice of tests.	Methods, Paragraph 7 (Page 7, Line 68-71)		

Data Availability	Yes (indicate where provided:	n/a	
State whether newly created datasets are available, including protocols for access or restriction on access.	Not available to protect patient privacy		
If data are publicly available, provide accession number in repository or DOI or URL.		n/a	Data is not publicly available
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a	Data is not publicly available

Code Availability	Yes (indicate where provided:	n/a	
For all newly generated code and software essential for replicating the main findings of the study:			
State whether the code or software is available.		n/a	No code/software is used
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a	No code/software is used

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/atm-20-6026